8-K: Bioxytran Secures $1.6 Million Investment to Advance Clinical Development and Extinguish Debt

Bioxytran, Inc. announces a $1.6 million investment from Triton Funds LP to settle debt, fund clinical trials, and for working capital, while management forfeits over $460,000 in accrued compensation.

Summary

• Bioxytran, Inc. has entered into a $1.6 million common stock closing agreement with Triton Funds LP.
• A portion of the proceeds, $805,000, will be used to settle an existing note.
• The remaining funds will support regulatory pre-clinical and clinical trials, as well as working capital needs.
• Management is forfeiting accrued salaries and expenses totaling over $460,000.
• Triton Funds will purchase up to 19.9% of Bioxytran's common stock, or 17,538,240 shares, based on 88,131,859 shares outstanding.
• The pricing is based on the lowest traded price of the securities 10 days prior to closing.
• A purchase fee of $400,000 and an administrative fee of $35,000 will be deducted from the investment.
• The shares will be issued pursuant to a selling shareholder prospectus on Form S-1 to be filed with the SEC within seven days of the closing date.
• Closing will occur once the company's upcoming registration statement on Form S-1 becomes effective.

Sentiment

Score: 7

Explanation: The announcement is moderately positive. The investment provides needed capital and resolves a debt issue. However, dilution is a concern, and the company's future success depends on clinical trial outcomes.

Positives

• The $1.6 million investment strengthens Bioxytran's financial position.
• Settling the $805,000 note removes a significant debt overhang.
• Funding for pre-clinical and clinical trials supports the advancement of Bioxytran's drug development programs.
• Management's forfeiture of over $460,000 in accrued compensation demonstrates commitment to the company's success.
• Triton Funds' continued investment signals confidence in Bioxytran's potential.

Negatives

• The investment involves the issuance of new shares, potentially diluting existing shareholders' equity.
• The investment includes a $400,000 purchase fee and a $35,000 administrative fee, reducing the net proceeds available to the company.
• The closing is contingent upon the effectiveness of the company's upcoming registration statement on Form S-1.

Risks

• The closing of the agreement is subject to certain conditions, including the effectiveness of the registration statement.
• The issuance of new shares could dilute existing shareholders' equity.
• The company's ability to successfully advance its clinical trials is subject to regulatory and scientific risks.
• The company's future financial performance depends on the successful development and commercialization of its drug candidates.

Future Outlook

The company anticipates that this financing removes the convertible overhang and should allow market driven price discovery, and that this investment is a stepping stone for follow on investment of a more substantial nature.

Management Comments

• 'Their investment showcases their commitment to the long-term success of Bioxytran,' commented CEO of Bioxytran Inc, Dr. David Platt.
• 'This gives us the momentum needed to move forward with our regulatory pathway and with our FDA trial of PLM, while at the same time testing a number of viruses with pandemic potential.'

Industry Context

The investment highlights growing interest in galectin antagonists as potential treatments for various diseases, including viral infections, fibrosis, and cancer. Triton Funds' recognition of the advancements in galectin science and Bioxytran's clinical trial data suggests a positive outlook for this therapeutic area.

Comparison to Industry Standards

• It's difficult to directly compare this specific financing to industry standards without knowing the exact stage of Bioxytran's clinical trials and the specific terms of the agreement.
• However, similar biotech companies raising capital at a pre-clinical or early clinical stage often face dilution, which is a common trade-off for securing funding.
• The management's decision to forfeit accrued compensation is a positive signal, indicating alignment with shareholder interests, which is often seen in companies seeking to improve investor confidence.
• Compared to other private placements in the biotech sector, the fees associated with this transaction ($400,000 purchase fee and $35,000 administrative fee) appear to be within a reasonable range, but the specific percentage would need to be compared to similar deals for a more accurate assessment.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• Employees benefit from the company's continued operation and advancement of its programs.
• Customers (potential patients) may benefit from the development of new treatments.
• Suppliers and creditors benefit from the company's improved financial stability.

Next Steps

• File a selling shareholder prospectus on Form S-1 with the SEC within seven days of the closing date.
• Await the effectiveness of the registration statement on Form S-1.
• Proceed with regulatory pre-clinical and clinical trials.
• Test a number of viruses with pandemic potential.

Key Dates